Inhibikase Therapeutics (NYSE:IKT - Get Free Report)'s stock had its "neutral" rating reiterated by stock analysts at HC Wainwright in a research note issued on Friday,Benzinga reports.
Inhibikase Therapeutics Stock Performance
IKT stock traded down $0.10 during mid-day trading on Friday, hitting $2.09. The company had a trading volume of 236,268 shares, compared to its average volume of 223,823. The firm has a market cap of $144.97 million, a PE ratio of -0.78 and a beta of 1.04. Inhibikase Therapeutics has a 12 month low of $1.12 and a 12 month high of $4.20. The stock's fifty day moving average price is $2.41 and its two-hundred day moving average price is $2.41.
Institutional Investors Weigh In On Inhibikase Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IKT. Stifel Financial Corp purchased a new position in shares of Inhibikase Therapeutics in the fourth quarter worth about $43,000. Jefferies Financial Group Inc. purchased a new position in Inhibikase Therapeutics in the 4th quarter valued at approximately $48,000. Alpine Global Management LLC bought a new stake in Inhibikase Therapeutics during the 4th quarter valued at $48,000. Caxton Corp bought a new stake in Inhibikase Therapeutics during the 4th quarter valued at $53,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Inhibikase Therapeutics during the fourth quarter worth $92,000. 3.81% of the stock is currently owned by institutional investors.
Inhibikase Therapeutics Company Profile
(
Get Free Report)
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
Read More
Before you consider Inhibikase Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.
While Inhibikase Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
